BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
8 results:

  • 1. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.
    Vanmechelen M; Lambrechts D; Van Brussel T; Verbiest A; Couchy G; Schöffski P; Dumez H; Debruyne PR; Lerut E; Machiels JP; Richard V; Albersen M; Verschaeve V; Oudard S; Méjean A; Wolter P; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2019 Apr; 17(2):e235-e246. PubMed ID: 30527746
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
    Go H; Kang MJ; Kim PJ; Lee JL; Park JY; Park JM; Ro JY; Cho YM
    Pathol Oncol Res; 2019 Jan; 25(1):51-58. PubMed ID: 28963640
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Autologous Stem-Cell Transplantation Without Hematopoietic Support for the treatment of Hematologic Malignancies in Jehovah's Witnesses.
    Ford PA; Grant SJ; Mick R; Keck G
    J Clin Oncol; 2015 May; 33(15):1674-9. PubMed ID: 25870085
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
    Rosenberg JE; Bambury RM; Van Allen EM; Drabkin HA; Lara PN; Harzstark AL; Wagle N; Figlin RA; Smith GW; Garraway LA; Choueiri T; Erlandsson F; Laber DA
    Invest New Drugs; 2014 Feb; 32(1):178-87. PubMed ID: 24242861
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.
    Wöhrle S; Weiss A; Ito M; Kauffmann A; Murakami M; Jagani Z; Thuery A; Bauer-Probst B; Reimann F; Stamm C; Pornon A; Romanet V; Guagnano V; Brümmendorf T; Sellers WR; Hofmann F; Roberts CW; Graus Porta D
    PLoS One; 2013; 8(10):e77652. PubMed ID: 24204904
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The role of pharmacogenomics in metastatic renal cell carcinoma.
    Castellano D; Virizuela JA; Cruz J; Sepulveda JM; Sáez MI; Paz-Ares L
    Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S29-32. PubMed ID: 22723081
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.